Analyst Joseph Stringer of Needham maintained a Buy rating on Vir Biotechnology, retaining the price target of $14.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Stringer has given his Buy rating due to a combination of factors including the progress in Vir Biotechnology’s Hepatitis Delta Virus (HDV) Phase 3 registrational program, known as the ECLIPSE trials. The company has fully initiated this program, with the pivotal ECLIPSE-1 trial expected to complete enrollment by the end of 2025, indicating a strong advancement in their clinical pipeline.
Additionally, Vir Biotechnology is making strides in its oncology T-cell engager (TCE) programs, with dose escalation ongoing for VIR-5518 and VIR-5500, and the initiation of enrollment for the VIR-5525 Phase 1 trial. These developments, alongside a robust cash balance of $892 million as of the second quarter of 2025, provide a solid financial foundation to support these initiatives, reinforcing the Buy rating.
In another report released today, Barclays also maintained a Buy rating on the stock with a $31.00 price target.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VIR in relation to earlier this year.